Meeting
2014 ASCO Annual Meeting
Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.
Authors
Robert B. Montgomery
University of Washington, Seattle, WA
Robert B. Montgomery , Mario A. Eisenberger , Elisabeth I. Heath , A. Oliver Sartor , Franklin Chu , Neal D. Shore , William Jeffery Edenfield , Alan J. Koletsky , David Uri Lipsitz , James S. Cochran , Luke T. Nordquist , Jennifer Roberts , Mary-Ellen Taplin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT# 01709734
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5029)
DOI
10.1200/jco.2014.32.15_suppl.5029
Abstract #
5029
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
First Author: Mary-Ellen Taplin
Poster
2014 Genitourinary Cancers Symposium
ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy.
First Author: Mary-Ellen Taplin
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
First Author: Johann S. De Bono